Pro Medicus

Pro Medicus is led by CEO and Co-Founder Dr. Sam Hupert, a medical practitioner who moved from clinical medicine into health software development. Co-Founder Anthony Hall, a computer scientist, continues to serve as a Non-Executive Director. This combination of clinical and technical expertise at the top has been central to the company's product design philosophy since its founding in 1983.

The core technology is Visage 7, a server-side rendering engine that processes images on a central server and streams an interactive, lossless view to any standard web browser or device. Traditional PACS systems require moving large datasets to a local workstation, causing latency and requiring powerful local hardware. The Visage architecture allows radiologists to access full-resolution scans on an iPad from anywhere, a feature that has become a critical competitive advantage in winning large US hospital contracts.

Pro Medicus generates nearly all of its revenue through long-term, subscription-based SaaS contracts for its Visage 7 enterprise imaging platform. These are multi-year agreements, typically with large private and academic hospital networks. The business operates with extremely low churn and gross margins that consistently exceed 99%, as additional usage has negligible marginal cost due to its proprietary streaming architecture.

Yes, the United States is the company's dominant market, accounting for the large majority of its revenue. Its largest contracts are with major US non-profit health systems and academic medical centers. The firm also maintains a growing European business, particularly in Germany and Switzerland, serviced out of its Berlin office, and it holds a foundational market position in its home country of Australia.

Pro Medicus argues its main competitive advantages are the speed and scalability of its proprietary Visage streaming technology, which is protected by intellectual property and built on a single, modern codebase. This technical architecture allows rapid deployment without large on-site hardware installations. The firm's ability to displace deeply entrenched legacy vendors like GE HealthCare and Philips in competitive public tenders suggests its technological edge translates into concrete commercial wins, as seen with contracts at Mass General Brigham and Trinity Health.

As a publicly listed operating company, Pro Medicus does not fund startups or manage external portfolios. Its capital allocation is targeted entirely toward internal R&D for its software platform and the operational scale-up of its sales and implementation teams, primarily in North America. It does not operate a venture arm or a fund-of-funds strategy.

Pro Medicus does not source 'deal flow' in the venture or private equity sense. As a public technology vendor, its business development consists of a direct sales force responding to formal Requests for Proposals (RFPs) from large hospital networks, primarily in the United States, seeking to replace or consolidate legacy imaging systems. Its wins are public record, often announced as material events on the ASX.